Radiotherapy for salivary gland cancer: REFCOR recommendations by the formal consensus method.

Hadrontherapy Radiotherapy Salivary gland cancer

Journal

European annals of otorhinolaryngology, head and neck diseases
ISSN: 1879-730X
Titre abrégé: Eur Ann Otorhinolaryngol Head Neck Dis
Pays: France
ID NLM: 101531465

Informations de publication

Date de publication:
28 Nov 2023
Historique:
medline: 30 11 2023
pubmed: 30 11 2023
entrez: 29 11 2023
Statut: aheadofprint

Résumé

To determine the indications for radiotherapy in salivary gland cancer and to specify the modalities and target radiation volumes. The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group which drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method. Postoperatively, radiotherapy to the primary tumor site±to the lymph nodes is indicated if one or more of the following adverse histoprognostic factors are present (risk>10% of locoregional recurrence): T3-T4 category, lymph node invasion, extraglandular invasion, close or positive surgical margins, high tumor grade, perineural invasion, vascular emboli, and/or bone invasion. Intensity-modulated radiation therapy (IMRT) is the gold standard. For unresectable cancers or inoperable patients, carbon ion hadrontherapy may be considered. Radiotherapy in salivary gland cancer is indicated in postoperative situations in case of adverse histoprognostic factors and for inoperable tumors.

Identifiants

pubmed: 38030445
pii: S1879-7296(23)00158-8
doi: 10.1016/j.anorl.2023.11.006
pii:
doi:

Types de publication

Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Auteurs

J Thariat (J)

Département de radiothérapie, centre François-Baclesse, Caen, France.

F-R Ferrand (FR)

French Armed Forces Biomedical Research Institute, 91220 Brétigny-sur-Orge, France; Département d'oncologie médicale, institut Gustave-Roussy, Villejuif, France.

N Fakhry (N)

Département d'ORL et chirurgie cervico-faciale, hôpital La Conception, AP-HM, Aix-Marseille University, 147, boulevard Baille, 13005 Marseille, France. Electronic address: Nicolas.fakhry@ap-hm.fr.

C Even (C)

Département d'oncologie médicale, institut Gustave-Roussy, Villejuif, France.

S Vergez (S)

Département de chirurgie, institut universitaire du cancer Toulouse - Oncopole, Toulouse, France; Département de chirurgie ORL et cervico-faciale, CHU de Toulouse-Larrey, université Toulouse III Paul-Sabatier, Toulouse, France.

E Chabrillac (E)

Département de chirurgie, institut universitaire du cancer Toulouse - Oncopole, Toulouse, France.

V Sarradin (V)

Département d'oncologie médicale, institut universitaire du cancer Toulouse - Oncopole, Toulouse, France.

L Digue (L)

Département d'oncologie médicale, hôpital Saint-André, Bordeaux, France.

I Troussier (I)

Département d'oncologie radiothérapie, centre de haute énergie, Nice, France.

R-J Bensadoun (RJ)

Département d'oncologie radiothérapie, centre de haute énergie, Nice, France.

Classifications MeSH